Lexicon Pharmaceuticals Inc (LXRX)
1.185
-0.02
(-1.66%)
USD |
NASDAQ |
Nov 05, 16:00
1.17
-0.02
(-1.27%)
After-Hours: 18:14
Lexicon Pharmaceuticals Enterprise Value: 225.13M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 225.13M |
| November 01, 2024 | 230.56M |
| October 31, 2024 | 494.44M |
| October 30, 2024 | 494.44M |
| October 29, 2024 | 523.36M |
| October 28, 2024 | 461.91M |
| October 25, 2024 | 440.22M |
| October 24, 2024 | 454.68M |
| October 23, 2024 | 461.91M |
| October 22, 2024 | 490.83M |
| October 21, 2024 | 494.44M |
| October 18, 2024 | 541.44M |
| October 17, 2024 | 516.13M |
| October 16, 2024 | 479.99M |
| October 15, 2024 | 436.61M |
| October 14, 2024 | 436.61M |
| October 11, 2024 | 418.53M |
| October 10, 2024 | 400.46M |
| October 09, 2024 | 378.77M |
| October 08, 2024 | 396.84M |
| October 07, 2024 | 396.84M |
| October 04, 2024 | 400.46M |
| October 03, 2024 | 371.54M |
| October 02, 2024 | 371.54M |
| October 01, 2024 | 360.69M |
| Date | Value |
|---|---|
| September 30, 2024 | 357.08M |
| September 27, 2024 | 367.92M |
| September 26, 2024 | 346.23M |
| September 25, 2024 | 335.39M |
| September 24, 2024 | 357.08M |
| September 23, 2024 | 360.69M |
| September 20, 2024 | 389.61M |
| September 19, 2024 | 400.46M |
| September 18, 2024 | 382.38M |
| September 17, 2024 | 375.15M |
| September 16, 2024 | 378.77M |
| September 13, 2024 | 404.07M |
| September 12, 2024 | 393.23M |
| September 11, 2024 | 400.46M |
| September 10, 2024 | 393.23M |
| September 09, 2024 | 393.23M |
| September 06, 2024 | 371.54M |
| September 05, 2024 | 375.15M |
| September 04, 2024 | 378.77M |
| September 03, 2024 | 371.54M |
| August 30, 2024 | 414.92M |
| August 29, 2024 | 440.22M |
| August 28, 2024 | 411.30M |
| August 27, 2024 | 411.30M |
| August 26, 2024 | 429.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.22M
Minimum
Nov 02 2020
1.146B
Maximum
Feb 02 2021
375.74M
Average
355.62M
Median
Jan 13 2023
Enterprise Value Benchmarks
| Viatris Inc | 29.63B |
| AIM ImmunoTech Inc | 8.843M |
| Perspective Therapeutics Inc | 530.78M |
| Protalix BioTherapeutics Inc | 69.53M |
| Armata Pharmaceuticals Inc | 170.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.43M |
| Revenue (Quarterly) | 1.647M |
| Total Expenses (Quarterly) | 57.00M |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -3.24K% |
| Earnings Yield | -65.82% |
| Normalized Earnings Yield | -65.82 |